ESR1 and breast cancer: Here, we report for the first time that the synergic reduction of LumA BC cell proliferation occurs with both CHK1 inhibitors, Tam, and CDK4/CDK6 inhibitors, thus suggesting that this combinatorial strategy could be effective in the treatment of ERα-positive BC sufferers.